Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 3Endocrine 3Genitourinary 2Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Gastrointestinal 1CNS 1Breast 1

Conditions

Glioblastoma 12Brain Neoplasms 6Glioma 3Gliosarcoma 2Carcinoma, Non-Small-Cell Lung 2Thyroid Carcinoma, Anaplastic 1Small Cell Lung Carcinoma 1Pheochromocytoma 1Paraganglioma 1Neuroendocrine Tumors 1Melanoma 1HER2-positive Metastatic Breast Cancer 1Astrocytoma 1Adenoviridae Infections 1Adenocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 7gallium Ga 68 dotatate 6lutetium Lu 177 dotatate 4Fluorodeoxyglucose F18 33-Iodobenzylguanidine 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3fluorodopa F 18 2Specimen Handling 2FAPI-46 2Everolimus 2Erlotinib Hydrochloride 2vandetanib 1romidepsin 1pertuzumab 1pentetreotide 1olaparib 1fludarabine phosphate 1entrectinib 1dactolisib 1cabozantinib 1atezolizumab 1arginyllysine 1amino-acid, glucose, and electrolyte solution 1alectinib 1Whole Body Imaging 1Tretinoin 1Respiratory Therapy 1Quality of Life 1Positron-Emission Tomography 1Patient Reported Outcome Measures 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × atezolizumab × CNS × Clear all
NCT04400474 2025-06-19

CABATEN

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
93 enrolled 17 charts
CNSEndocrineHead & NeckNET

Adenocarcinoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡